



**PRESS RELEASE
FOR IMMEDIATE RELEASE**

**Medicago CEO to join the Premier of Quebec, Jean Charest,
at International Conference in China**

Quebec City, Quebec, August 5, 2008 — Medicago Inc. (TSX-V: MDG) today announced that its President and CEO, Mr. Andy Sheldon, is a member of the delegation that will represent the province of Québec at the 4th Conference of Heads of Government of Partner Regions, being held in Jinan, China from August 5-8, 2008. Led by Mr. Jean Charest, the Premier of Québec, and Ms. Monique Gagnon-Tremblay, International Relations Minister, the Quebec delegation will consist of six Quebec-based companies, including Medicago as the only life sciences company. Mr. Sheldon will meet with health officials of the province of Shandong to present Medicago's proprietary plant-based vaccine development and production technologies and how the Company is able to address pandemic planning in the most efficient and effective manner.

"Ongoing outbreaks of H5N1 Avian Influenza in Asia pose a significant risk for a pandemic emphasizing the importance of preparedness in this region of the world," said Andy Sheldon, President and CEO of Medicago. "We believe our plant-based vaccine manufacturing technology can help China prepare for future outbreaks of H5N1 and prevent or reduce the impact of a pandemic."

During the conference, the Heads of Government of Upper Austria, Bavaria, Western Cape, Georgia, Shandong, São Paulo, and Québec will gather to discuss the development of action plans to promote the adoption of government policies that reconcile economic development, social protection, the sustainable preservation of resources essential for life and the promotion of cultural diversity for future generations. The theme for this year's conference will be "Health and Medical Care" and "Building a Resource-Conserving Society".

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward-Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

- 30 -

The TSX Venture Exchange assumes no responsibility for the content or accuracy of this press release

Contact:

Medicago, Inc.
Andy Sheldon
President and CEO
(418) 658-9393

Investor relations

The Equicom Group Inc.
Arianna Vanin
(514) 844-4680
avanin@equicomgroup.com